CN114028420A - Externally applied glucosamine chondroitin nano preparation and preparation method thereof - Google Patents
Externally applied glucosamine chondroitin nano preparation and preparation method thereof Download PDFInfo
- Publication number
- CN114028420A CN114028420A CN202111621498.XA CN202111621498A CN114028420A CN 114028420 A CN114028420 A CN 114028420A CN 202111621498 A CN202111621498 A CN 202111621498A CN 114028420 A CN114028420 A CN 114028420A
- Authority
- CN
- China
- Prior art keywords
- chondroitin
- glucosamine
- nano
- preparation
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002567 Chondroitin Polymers 0.000 title claims abstract description 57
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 title claims abstract description 57
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 title claims abstract description 43
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960002442 glucosamine Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 54
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000000463 material Substances 0.000 claims abstract description 51
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims abstract description 30
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000002502 liposome Substances 0.000 claims abstract description 25
- 210000000845 cartilage Anatomy 0.000 claims abstract description 23
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 20
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 20
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 18
- 239000003906 humectant Substances 0.000 claims abstract description 18
- 150000002632 lipids Chemical class 0.000 claims abstract description 18
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 18
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims abstract description 16
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims abstract description 16
- 229950006780 n-acetylglucosamine Drugs 0.000 claims abstract description 16
- 241000251730 Chondrichthyes Species 0.000 claims abstract description 15
- 229960000541 cetyl alcohol Drugs 0.000 claims abstract description 15
- 239000008367 deionised water Substances 0.000 claims abstract description 15
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 15
- 239000002480 mineral oil Substances 0.000 claims abstract description 15
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 15
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229920002545 silicone oil Polymers 0.000 claims abstract description 15
- 239000003755 preservative agent Substances 0.000 claims abstract description 11
- 230000002335 preservative effect Effects 0.000 claims abstract description 11
- 241000283690 Bos taurus Species 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims abstract description 8
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 42
- 239000012528 membrane Substances 0.000 claims description 22
- 238000001816 cooling Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 17
- 238000010438 heat treatment Methods 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 239000011265 semifinished product Substances 0.000 claims description 14
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 10
- 238000004945 emulsification Methods 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 238000001125 extrusion Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229920000515 polycarbonate Polymers 0.000 claims description 7
- 239000004417 polycarbonate Substances 0.000 claims description 7
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 3
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 229940116229 borneol Drugs 0.000 claims description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 3
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 235000019477 peppermint oil Nutrition 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 3
- -1 platinum methyl ester Chemical class 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000004054 inflammatory process Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000012466 permeate Substances 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 description 14
- 210000001503 joint Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000000518 sarcolemma Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
The invention discloses an externally applied coating glucosamine chondroitin nano preparation and a preparation method thereof, wherein the externally applied coating glucosamine chondroitin nano preparation comprises a nano liposome and an inner material; the inner material comprises the following components in percentage by mass: 4-6% of glycerol, 3-6% of propylene glycol, 5-12% of N-acetyl-D-glucosamine, 2-4% of a humectant, 8-10% of a penetration enhancer, 2-8% of shark cartilage chondroitin sulfate, 1-3% of bovine bone chondroitin, 8-12% of a lipid material, 2-6% of stearyl alcohol, 2-6% of cetyl alcohol, 8-10% of mineral oil, 2-4% of silicone oil, 2-4% of an emulsifier, 1.2-1.6% of a preservative, and the balance of deionized water. The particle size is smaller, the transdermal rate is high, the use amount of active ingredients is small, the production cost is saved, glucosamine and chondroitin can quickly permeate into joints, the joints are lubricated, the pain and inflammation of osteoarthritis are relieved, and cartilage tissues are repaired.
Description
Technical Field
The invention relates to an externally applied glucosamine chondroitin nano preparation and a preparation method thereof.
Background
Osteoarthritis is degenerative disease of bone joints, the diseased part is the knee joint, osteoarthritis is one of diseases with high disability rate, and the social hazard is great. Modern medicine finds that the most fundamental causes of osteoarticular diseases are the abrasion of articular cartilage and the loss of synovial fluid of osteoarticular joints, which are greatly related to the loss of glucosamine and chondroitin in vivo.
Glucosamine, known by the chemical name N-acetyl-D-glucosamine, is considered by the medical community as the only substance that can fundamentally improve osteoarticular diseases so far. Glucosamine has high affinity for articular cartilage and can permeate into cartilage matrix. Exogenous glucosamine supplementation can not only stimulate proteoglycan production by cartilage cells to repair cartilage tissues, but also inhibit the activities of collagenase and phospholipase A2 which damage cartilage, prevent cartilage degradation, and block the pathological development process of osteoarthritis.
Chondroitin, also known as chondroitin sulfate, is an acidic mucopolysaccharide found in the cartilage, tendons, sarcolemma and blood vessel walls of humans and animals. Chondroitin sulfate is an important component of connective tissue and has a variety of pharmacological effects. Chondroitin sulfate can absorb water molecules into proteoglycan molecules, so that cartilage is thickened, synovial fluid at joints is increased, the shock absorption capacity of joints is enhanced, and impact and friction of external force on the joints in daily activities are relieved; chondroitin sulfate can repair joint damage caused by hard friction between bones; enzymes such as collagenase, elastase and cathepsin degrade the collagen fiber network supporting cartilage, and finally, cartilage is degraded, while chondroitin sulfate can inhibit the activity of the above enzymes, thereby protecting cartilage.
Modern medical research shows that glucosamine and chondroitin are combined to strengthen various media in cartilage tissues, inhibit the generation of free radicals, inhibit the activity of metalloproteinase for degrading cartilage and stabilize lysosome membranes, thereby playing the roles of resisting inflammation and easing pain. The combination of the two can also promote the synthesis of proteoglycan and collagen in cartilage, maintain the stability of cartilage extracellular matrix, and indirectly play a role in eliminating inflammation and relieving pain. Clinical practice also proves that the two drugs are closely combined to supplement each other and cooperate with each other, and the effect of '1 +1 > 2' can be achieved in treatment.
The prior art has the following disadvantages: most of glucosamine chondroitin products sold on the market at present adopt a high-speed homogenizing and dispersing emulsifying machine for emulsification, the emulsification level can only reach a sub-nanometer level, nanometer emulsification particle sizes cannot be formed, effective ingredients can only stay on the surface of a skin cuticle, the maximum effect of the effective ingredients cannot be exerted, and the using amount of the effective ingredients is large.
Disclosure of Invention
The invention aims to solve the technical problems that glucosamine chondroitin products in the prior art are poor in transdermal absorption, active ingredients can only stay on the surface of a skin cuticle layer and cannot reach the deep part of a joint, and the like, and provides an externally applied coated glucosamine chondroitin nano preparation which is smaller in particle size than the existing glucosamine chondroitin products, high in transdermal permeability, small in use amount of the active ingredients, capable of saving production cost, capable of rapidly permeating glucosamine and chondroitin to the joint, lubricating the joint, repairing cartilage and rapidly relieving pain and a preparation method thereof.
In order to solve the problems, the invention adopts the following technical scheme:
a topical nanometer preparation for applying glucosamine chondroitin comprises nanometer liposome and inner material; the inner material comprises the following components in percentage by mass: 4-6% of glycerol, 3-6% of propylene glycol, 5-12% of N-acetyl-D-glucosamine, 2-4% of a humectant, 8-10% of a penetration enhancer, 2-8% of shark cartilage chondroitin sulfate, 1-3% of bovine bone chondroitin, 8-12% of a lipid material, 2-6% of stearyl alcohol, 2-6% of cetyl alcohol, 8-10% of mineral oil, 2-4% of silicone oil, 2-4% of an emulsifier, 1.2-1.6% of a preservative, and the balance of deionized water.
Preferably, the humectant is one or a mixture of glycerol, propylene glycol, butanediol and the like.
Preferably, the penetration enhancer is one or a mixture of more of menthol, borneol, peppermint oil and the like.
Preferably, the lipid material is a mixture of hydrogenated lecithin and egg yolk lecithin.
Preferably, the emulsifier is a nonionic surfactant, and comprises one or a mixture of several of span, tween, ceteareth and the like.
Preferably, the preservative is one or a mixture of more of platinum methyl ester, phenoxyethanol, p-hydroxyacetophenone and the like.
Preferably, the uniform particle size of the nanoliposome after the inner material is coated is 80-150 nm.
Preferably, the preparation method of the externally applied glucosamine chondroitin nano preparation comprises the following steps: (1) mixing lipid material, stearyl alcohol, cetyl alcohol, mineral oil, silicone oil, and emulsifier, heating to 75 deg.C, stirring, and dispersing to form oil phase; (2) adding glycerol, butanediol, propylene glycol, N-acetyl-D-glucosamine, humectant, penetration enhancer, shark chondroitin sulfate, and ox chondroitin into deionized water, heating to 75 deg.C, and stirring to obtain water phase; (3) and (3) placing the oil phase in the water phase in a vacuum homogenizing emulsifying pot, starting a fixed type vacuumizing homogenizing stirring blade, and homogenizing and stirring at the stirring speed of 800rpm, 2300rpm and 0.04MPa for 5 min. Continuously stirring under vacuum condition, cooling to 30 deg.C, releasing vacuum pressure, and adding antiseptic to obtain semi-finished product; (4) quantitatively adding the semi-finished product into a high-pressure homogenizer in batches of 2-5 by a pump, starting a pressure and temperature control internal circulation machine to carry out secondary homogenizing emulsification, controlling the pressure at 10-150Mpa, controlling the temperature of the internal circulation of the material body at 3-8 ℃, when the appearance of the material body is creamy white paste, introducing the cream into an inlet of a liposome filter membrane extruder, adjusting the extrusion pressure of the liposome filter membrane extruder by using compressed gas, filtering by matching with a polycarbonate filter membrane at high pressure, and cooling by a cooling device to obtain the finished product.
The externally applied glucosamine chondroitin nano preparation and the preparation method thereof have the beneficial effects that: by adopting liposome nanotechnology, the particle size range of the nanoparticle carrying glucosamine and chondroitin in the preparation is 80-150nm, the particle size is smaller than that of the existing glucosamine chondroitin product, the transdermal rate is high, the use amount of effective components is small, the production cost is saved, and the glucosamine and chondroitin can quickly permeate into joints, lubricate the joints, repair cartilages and quickly relieve pain.
Detailed Description
A topical nanometer preparation for applying glucosamine chondroitin and its preparation method are provided, which comprises nanometer liposome and inner material; the inner material comprises the following components in percentage by mass: 4-6% of glycerol, 3-6% of propylene glycol, 5-12% of N-acetyl-D-glucosamine, 2-4% of a humectant, 8-10% of a penetration enhancer, 2-8% of shark cartilage chondroitin sulfate, 1-3% of bovine bone chondroitin, 8-12% of a lipid material, 2-6% of stearyl alcohol, 2-6% of cetyl alcohol, 8-10% of mineral oil, 2-4% of silicone oil, 2-4% of an emulsifier, 1.2-1.6% of a preservative, and the balance of deionized water.
As a preferable technical scheme, the humectant is one or a mixture of more of glycerin, propylene glycol, butanediol and the like.
As a preferable technical scheme, the penetration enhancer is one or a mixture of more of menthol, borneol, peppermint oil and the like.
As a preferred technical scheme, the lipid material is a mixture consisting of hydrogenated lecithin and egg yolk lecithin.
As a preferable technical scheme, the emulsifier is a non-ionic surfactant and comprises one or a mixture of more of span, Tween, ceteareth and the like.
As a preferable technical scheme, the preservative is one or a mixture of more of platinum methyl ester, phenoxyethanol, p-hydroxyacetophenone and the like.
As a preferable technical scheme, the uniform particle size of the nano liposome after the inner material is coated is 80-150 nm.
As a preferred technical scheme, the preparation method of the externally applied glucosamine chondroitin nano preparation comprises the following steps: (1) mixing lipid material, stearyl alcohol, cetyl alcohol, mineral oil, silicone oil, and emulsifier, heating to 75 deg.C, stirring, and dispersing to form oil phase; (2) adding glycerol, butanediol, propylene glycol, N-acetyl-D-glucosamine, humectant, penetration enhancer, shark chondroitin sulfate, and ox chondroitin into deionized water, heating to 75 deg.C, and stirring to obtain water phase; (3) and (3) placing the oil phase in the water phase in a vacuum homogenizing emulsifying pot, starting a fixed type vacuumizing homogenizing stirring blade, and homogenizing and stirring at the stirring speed of 800rpm, 2300rpm and 0.04MPa for 5 min. Continuously stirring under vacuum condition, cooling to 30 deg.C, releasing vacuum pressure, and adding antiseptic to obtain semi-finished product; (4) quantitatively adding the semi-finished product into a high-pressure homogenizer in batches of 2-5 by a pump, starting a pressure and temperature control internal circulation machine to carry out secondary homogenizing emulsification, controlling the pressure at 10-150Mpa, controlling the temperature of the internal circulation of the material body at 3-8 ℃, when the appearance of the material body is creamy white paste, introducing the cream into an inlet of a liposome filter membrane extruder, adjusting the extrusion pressure of the liposome filter membrane extruder by using compressed gas, filtering by matching with a polycarbonate filter membrane at high pressure, and cooling by a cooling device to obtain the finished product.
Example 1, the present invention relates to a nano-formulation of glucosamine chondroitin for external use for relieving pain and inflammation of osteoarthritis and repairing cartilage tissue, comprising nano-liposomes and an inner material; the inner material comprises the following components in percentage by mass: 4% of glycerol, 3% of propylene glycol, 5% of N-acetyl-D-glucosamine, 2% of a humectant, 8% of a penetration enhancer, 2% of shark chondroitin sulfate, 1% of bovine chondroitin, 8% of a lipid material, 2% of stearyl alcohol, 2% of cetyl alcohol, 8% of mineral oil, 2% of silicone oil, 2% of an emulsifier, 1.2% of a preservative and 48.8% of deionized water.
The invention also relates to a preparation method of the externally applied glucosamine chondroitin nano preparation, which comprises the following steps:
1) mixing lipid material, stearyl alcohol, cetyl alcohol, mineral oil, silicone oil, and emulsifier, heating to 75 deg.C, stirring, and dispersing to form oil phase;
2) adding glycerol, butanediol, propylene glycol, N-acetyl-D-glucosamine, humectant, penetration enhancer, shark chondroitin sulfate, and ox chondroitin into deionized water, heating to 75 deg.C, and stirring to obtain water phase;
3) and (3) placing the oil phase in the water phase in a vacuum homogenizing emulsifying pot, starting a fixed type vacuumizing homogenizing stirring blade, and homogenizing and stirring at the stirring speed of 800rpm, 2300rpm and 0.04MPa for 5 min. Continuously stirring under vacuum condition, cooling to 30 deg.C, releasing vacuum pressure, and adding antiseptic to obtain semi-finished product;
4) quantitatively adding the semi-finished product into a high-pressure homogenizer in batches of 2-5 by a pump, starting a pressure and temperature control internal circulation machine to carry out secondary homogenizing emulsification, controlling the pressure at 10-150Mpa, controlling the temperature of the internal circulation of the material body at 3-8 ℃, when the appearance of the material body is creamy white paste, introducing the cream into an inlet of a liposome filter membrane extruder, adjusting the extrusion pressure of the liposome filter membrane extruder by using compressed gas, filtering by matching with a polycarbonate filter membrane at high pressure, and cooling by a cooling device to obtain the finished product.
Embodiment 2, the present invention relates to a nano-formulation of glucosamine chondroitin for external use for relieving pain and inflammation of osteoarthritis and repairing cartilage tissue, comprising nano-liposomes and an inner material; the inner material comprises the following components in percentage by mass: 5% of glycerol, 5% of propylene glycol, 10% of N-acetyl-D-glucosamine, 4% of a humectant, 8% of a penetration enhancer, 3% of shark chondroitin sulfate, 1.5% of bovine chondroitin, 8% of a lipid material, 2% of stearyl alcohol, 2% of cetyl alcohol, 8% of mineral oil, 2% of silicone oil, 2% of an emulsifier, 1.2% of a preservative and 38.3% of deionized water.
The invention also relates to a preparation method of the externally applied glucosamine chondroitin nano preparation, which comprises the following steps:
1) mixing lipid material, stearyl alcohol, cetyl alcohol, mineral oil, silicone oil, and emulsifier, heating to 75 deg.C, stirring, and dispersing to form oil phase;
2) adding glycerol, butanediol, propylene glycol, N-acetyl-D-glucosamine, humectant, penetration enhancer, shark chondroitin sulfate, and ox chondroitin into deionized water, heating to 75 deg.C, and stirring to obtain water phase;
3) and (3) placing the oil phase in the water phase in a vacuum homogenizing emulsifying pot, starting a fixed type vacuumizing homogenizing stirring blade, and homogenizing and stirring at the stirring speed of 800rpm, 2300rpm and 0.04MPa for 5 min. Continuously stirring under vacuum condition, cooling to 30 deg.C, releasing vacuum pressure, and adding antiseptic to obtain semi-finished product;
4) quantitatively adding the semi-finished product into a high-pressure homogenizer in batches of 2-5 by a pump, starting a pressure and temperature control internal circulation machine to carry out secondary homogenizing emulsification, controlling the pressure at 10-150Mpa, controlling the temperature of the internal circulation of the material body at 3-8 ℃, when the appearance of the material body is creamy white paste, introducing the cream into an inlet of a liposome filter membrane extruder, adjusting the extrusion pressure of the liposome filter membrane extruder by using compressed gas, filtering by matching with a polycarbonate filter membrane at high pressure, and cooling by a cooling device to obtain the finished product.
Embodiment 3, the present invention relates to a nano-formulation of glucosamine chondroitin for external use for relieving pain and inflammation of osteoarthritis and repairing cartilage tissue, comprising nano-liposomes and an inner material; the inner material comprises the following components in percentage by mass: 5.5% of glycerol, 5% of propylene glycol, 12% of N-acetyl-D-glucosamine, 4% of a humectant, 10% of a penetration enhancer, 6% of shark chondroitin sulfate, 3% of bovine chondroitin, 12% of a lipid material, 4% of stearyl alcohol, 6% of cetyl alcohol, 9% of mineral oil, 3% of silicone oil, 3% of an emulsifier, 1.4% of a preservative and 16.1% of deionized water.
The invention also relates to a preparation method of the externally applied glucosamine chondroitin nano preparation, which comprises the following steps:
1) mixing lipid material, stearyl alcohol, cetyl alcohol, mineral oil, silicone oil, and emulsifier, heating to 75 deg.C, stirring, and dispersing to form oil phase;
2) adding glycerol, butanediol, propylene glycol, N-acetyl-D-glucosamine, humectant, penetration enhancer, shark chondroitin sulfate, and ox chondroitin into deionized water, heating to 75 deg.C, and stirring to obtain water phase;
3) and (3) placing the oil phase in the water phase in a vacuum homogenizing emulsifying pot, starting a fixed type vacuumizing homogenizing stirring blade, and homogenizing and stirring at the stirring speed of 800rpm, 2300rpm and 0.04MPa for 5 min. Continuously stirring under vacuum condition, cooling to 30 deg.C, releasing vacuum pressure, and adding antiseptic to obtain semi-finished product;
4) quantitatively adding the semi-finished product into a high-pressure homogenizer in batches of 2-5 by a pump, starting a pressure and temperature control internal circulation machine to carry out secondary homogenizing emulsification, controlling the pressure at 10-150Mpa, controlling the temperature of the internal circulation of the material body at 3-8 ℃, when the appearance of the material body is creamy white paste, introducing the cream into an inlet of a liposome filter membrane extruder, adjusting the extrusion pressure of the liposome filter membrane extruder by using compressed gas, filtering by matching with a polycarbonate filter membrane at high pressure, and cooling by a cooling device to obtain the finished product.
Embodiment 4, the present invention relates to a nano-formulation of glucosamine chondroitin for external use for relieving pain and inflammation of osteoarthritis and repairing cartilage tissue, comprising nano-liposomes and an inner material; the inner material comprises the following components in percentage by mass: 5% of glycerol, 6% of propylene glycol, 8% of N-acetyl-D-glucosamine, 3% of a humectant, 9% of a penetration enhancer, 3.4% of shark chondroitin sulfate, 1.2% of bovine chondroitin, 10% of a lipid material, 3% of stearyl alcohol, 3% of cetyl alcohol, 8% of mineral oil, 2% of silicone oil, 2% of an emulsifier, 1.2% of a preservative and 35.2% of deionized water.
The invention also relates to a preparation method of the externally applied glucosamine chondroitin nano preparation, which comprises the following steps:
1) mixing lipid material, stearyl alcohol, cetyl alcohol, mineral oil, silicone oil, and emulsifier, heating to 75 deg.C, stirring, and dispersing to form oil phase;
2) adding glycerol, butanediol, propylene glycol, N-acetyl-D-glucosamine, humectant, penetration enhancer, shark chondroitin sulfate, and ox chondroitin into deionized water, heating to 75 deg.C, and stirring to obtain water phase;
3) and (3) placing the oil phase in the water phase in a vacuum homogenizing emulsifying pot, starting a fixed type vacuumizing homogenizing stirring blade, and homogenizing and stirring at the stirring speed of 800rpm, 2300rpm and 0.04MPa for 5 min. Continuously stirring under vacuum condition, cooling to 30 deg.C, releasing vacuum pressure, and adding antiseptic to obtain semi-finished product;
4) quantitatively adding the semi-finished product into a high-pressure homogenizer in batches of 2-5 by a pump, starting a pressure and temperature control internal circulation machine to carry out secondary homogenizing emulsification, controlling the pressure at 10-150Mpa, controlling the temperature of the internal circulation of the material body at 3-8 ℃, when the appearance of the material body is creamy white paste, introducing the cream into an inlet of a liposome filter membrane extruder, adjusting the extrusion pressure of the liposome filter membrane extruder by using compressed gas, filtering by matching with a polycarbonate filter membrane at high pressure, and cooling by a cooling device to obtain the finished product.
In the present invention, an experimental comparison was made, which is as follows:
a. case selection: 27 men and 29 women in the treatment group are aged 45-70 years old;
b. the control group comprises 25 men and 31 women, and the age is 45-70 years. The age and the proportion of male and female in the two groups are balanced, the difference is not significant (P is more than 0.05), and the two groups have comparability.
c. The treatment method comprises the following steps: the joint of the treatment group is coated with the product; the ibuprofen sustained-release capsule is orally taken in a control group.
Experimental comparison data are as follows:
from the comparison of the experimental data in the above table, it can be seen that: compared with the control data of the treatment group using the ibuprofen sustained-release capsule, the treatment group using the product of the invention has better use effect than the control group using the ibuprofen sustained-release capsule.
The externally applied glucosamine chondroitin nano preparation and the preparation method thereof have the following advantages that: the grain diameter is smaller than that of the existing glucosamine chondroitin product, the transdermal rate is high, the use amount of active ingredients is small, the production cost is saved, and glucosamine chondroitin and chondroitin can quickly permeate into joints, lubricate the joints, repair cartilages and quickly relieve pain.
The above description is only an embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that are not thought of through the inventive work should be included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope defined by the claims.
Claims (8)
1. An externally applied glucosamine chondroitin nano preparation is characterized in that: comprises nano liposome and inner material; the inner material comprises the following components in percentage by mass: 4-6% of glycerol, 3-6% of propylene glycol, 5-12% of N-acetyl-D-glucosamine, 2-4% of a humectant, 8-10% of a penetration enhancer, 2-8% of shark cartilage chondroitin sulfate, 1-3% of bovine bone chondroitin, 8-12% of a lipid material, 2-6% of stearyl alcohol, 2-6% of cetyl alcohol, 8-10% of mineral oil, 2-4% of silicone oil, 2-4% of an emulsifier, 1.2-1.6% of a preservative, and the balance of deionized water.
2. The topical glucosamine chondroitin nano-preparation according to claim 1, wherein: the humectant is one or a mixture of glycerol, propylene glycol, butanediol, etc.
3. The topical glucosamine chondroitin nano-preparation according to claim 1, wherein: the penetration enhancer is one or more of menthol, borneol, peppermint oil and the like.
4. The topical glucosamine chondroitin nano-preparation according to claim 1, wherein: the lipid material is a mixture of hydrogenated lecithin and egg yolk lecithin.
5. The topical glucosamine chondroitin nano-preparation according to claim 1, wherein: the emulsifier is nonionic surfactant, and comprises one or more of span, tween, ceteareth and the like.
6. The topical glucosamine chondroitin nano-preparation according to claim 1, wherein: the preservative is one or a mixture of more of platinum methyl ester, phenoxyethanol, p-hydroxyacetophenone and the like.
7. The topical glucosamine chondroitin nano-preparation according to claim 1, wherein: the uniform particle size of the nano liposome after the inner material is wrapped is 80-150 nm.
8. A preparation method of an externally applied glucosamine chondroitin nano preparation is characterized by comprising the following steps: the method comprises the following steps: (1) mixing lipid material, stearyl alcohol, cetyl alcohol, mineral oil, silicone oil, and emulsifier, heating to 75 deg.C, stirring, and dispersing to form oil phase; (2) adding glycerol, butanediol, propylene glycol, N-acetyl-D-glucosamine, humectant, penetration enhancer, shark chondroitin sulfate, and ox chondroitin into deionized water, heating to 75 deg.C, and stirring to obtain water phase; (3) and (3) placing the oil phase in the water phase in a vacuum homogenizing emulsifying pot, starting a fixed type vacuumizing homogenizing stirring blade, and homogenizing and stirring at the stirring speed of 800rpm, 2300rpm and 0.04MPa for 5 min. Continuously stirring under vacuum condition, cooling to 30 deg.C, releasing vacuum pressure, and adding antiseptic to obtain semi-finished product; (4) quantitatively adding the semi-finished product into a high-pressure homogenizer in batches of 2-5 by a pump, starting a pressure and temperature control internal circulation machine to carry out secondary homogenizing emulsification, controlling the pressure at 10-150Mpa, controlling the temperature of the internal circulation of the material body at 3-8 ℃, when the appearance of the material body is creamy white paste, introducing the cream into an inlet of a liposome filter membrane extruder, adjusting the extrusion pressure of the liposome filter membrane extruder by using compressed gas, filtering by matching with a polycarbonate filter membrane at high pressure, and cooling by a cooling device to obtain the finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111621498.XA CN114028420A (en) | 2021-12-28 | 2021-12-28 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111621498.XA CN114028420A (en) | 2021-12-28 | 2021-12-28 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114028420A true CN114028420A (en) | 2022-02-11 |
Family
ID=80147250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111621498.XA Pending CN114028420A (en) | 2021-12-28 | 2021-12-28 | Externally applied glucosamine chondroitin nano preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114028420A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300634A (en) * | 2022-09-05 | 2022-11-08 | 淄博佐佑健身器材有限公司 | Liquid silica gel containing glucosamine chondroitin and preparation method and application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002154968A (en) * | 2000-11-21 | 2002-05-28 | Noriyuki Oikawa | Composition for preventing or curing arthritis, or for improving symptom of arthritis |
| CN1562073A (en) * | 2003-05-07 | 2005-01-12 | 汤毅 | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate |
| CN102293738A (en) * | 2011-08-10 | 2011-12-28 | 济南强生生物科技有限公司 | External preparation for and method treating arthritis |
| CN105193837A (en) * | 2015-09-16 | 2015-12-30 | 浙江康多利药业有限公司 | Cream preparation for preventing and treating joint diseases and preparation method thereof |
| CN106075408A (en) * | 2016-07-26 | 2016-11-09 | 上海建华精细生物制品有限公司 | Articular cavity class extracellular matrix polysaccharide nano injection liquid and preparation method thereof |
| CN106580869A (en) * | 2015-10-14 | 2017-04-26 | 深圳澳美制药技术开发有限公司 | Isoconeazole nitrate liposome nanoparticles creams and preparation method of the same |
| CN107362177A (en) * | 2017-09-07 | 2017-11-21 | 威海盛朗生物科技有限公司 | Drug component, ointment and plaster for treatment of arthritis |
| CN107802508A (en) * | 2017-11-01 | 2018-03-16 | 武汉百思凯瑞纳米科技有限公司 | A kind of cationic-liposome nano-composition and its preparation method and application |
| CN109464651A (en) * | 2019-01-02 | 2019-03-15 | 淄博职业学院 | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine |
| CN111280447A (en) * | 2018-12-07 | 2020-06-16 | 解冰 | Composite nanometer preparation for treating and recovering bone joint function and preparation method thereof |
-
2021
- 2021-12-28 CN CN202111621498.XA patent/CN114028420A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002154968A (en) * | 2000-11-21 | 2002-05-28 | Noriyuki Oikawa | Composition for preventing or curing arthritis, or for improving symptom of arthritis |
| CN1562073A (en) * | 2003-05-07 | 2005-01-12 | 汤毅 | Non-injection preparation containing medium and/or low molecular weight chondroitin sulfate |
| CN102293738A (en) * | 2011-08-10 | 2011-12-28 | 济南强生生物科技有限公司 | External preparation for and method treating arthritis |
| CN105193837A (en) * | 2015-09-16 | 2015-12-30 | 浙江康多利药业有限公司 | Cream preparation for preventing and treating joint diseases and preparation method thereof |
| CN106580869A (en) * | 2015-10-14 | 2017-04-26 | 深圳澳美制药技术开发有限公司 | Isoconeazole nitrate liposome nanoparticles creams and preparation method of the same |
| CN106075408A (en) * | 2016-07-26 | 2016-11-09 | 上海建华精细生物制品有限公司 | Articular cavity class extracellular matrix polysaccharide nano injection liquid and preparation method thereof |
| CN107362177A (en) * | 2017-09-07 | 2017-11-21 | 威海盛朗生物科技有限公司 | Drug component, ointment and plaster for treatment of arthritis |
| CN107802508A (en) * | 2017-11-01 | 2018-03-16 | 武汉百思凯瑞纳米科技有限公司 | A kind of cationic-liposome nano-composition and its preparation method and application |
| CN111280447A (en) * | 2018-12-07 | 2020-06-16 | 解冰 | Composite nanometer preparation for treating and recovering bone joint function and preparation method thereof |
| CN109464651A (en) * | 2019-01-02 | 2019-03-15 | 淄博职业学院 | A kind of amelioration of disease induced by metabolic disorder in cartilage healthy food and composite medicine |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300634A (en) * | 2022-09-05 | 2022-11-08 | 淄博佐佑健身器材有限公司 | Liquid silica gel containing glucosamine chondroitin and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106691889B (en) | High-skin-retention ceramide nano composition and preparation method and application thereof | |
| KR102621819B1 (en) | Nano multilamella liposome containg skin lipid ingredient and manufacturing method thereof | |
| US7883726B2 (en) | Skin care compositions with botanic seed oils | |
| JP7366985B2 (en) | Methods of treating signs of skin aging and moisturizing the skin | |
| CN114028420A (en) | Externally applied glucosamine chondroitin nano preparation and preparation method thereof | |
| US20150283080A1 (en) | Stabilized dermatological delivery system for active ingredient compositions for topical administration to the skin | |
| Souto et al. | Lipid-polymeric films: Composition, production and applications in wound healing and skin repair | |
| CN114028260B (en) | Ceramide E emulsifier, preparation method thereof and application thereof in cosmetics | |
| KR20190105313A (en) | Cosmetic composition for improving skin comprising core-shell nanocapsule with polydeoxyribonucleotide from salmom and method for preparing the same | |
| FR2977494A1 (en) | Composition, useful for treating skin wounds and irritation in mammals, preferably humans or horses, ophthalmic surgery including glaucoma and cataract, comprises a mixture of hyaluronic acids having different molecular weights | |
| JP2009029806A (en) | Use of fat-soluble extract of odontella aurita for restructuring skin, composition for use and cosmetic method using the extract | |
| US9173940B1 (en) | Mixture of betamethasone and tranilast with a transdermal gel for scar treatment | |
| JP6915048B2 (en) | Use of Arbutus Uned fruit extract as a cosmetic | |
| Guermech et al. | Development and assessment of lipidic nanoemulsions containing sodium hyaluronate and indomethacin | |
| KR101446706B1 (en) | Composition for skin rejuvenation comprising FGF | |
| CN105012184A (en) | Cosmetic composition for regulating cutin skin | |
| CN115429713A (en) | Moisturizing, repairing and anti-aging composition containing ceramide and preparation method thereof | |
| KR20160071077A (en) | Natural liposome comprising hyaluronic acid, process for the preparation thereof, and cosmetic composition comprising the same | |
| WO2008051557A2 (en) | Methods and compositions for treatment of skin conditions | |
| JPH08163983A (en) | Hyarulonic acid production promoter | |
| JP2002302414A (en) | Sphingolipid structural matter-containing emulsified composition and method for producing the same | |
| EP1353645B1 (en) | Method for the production and use of a cream containing vitamin-a. | |
| CN111588658A (en) | Ginkgo extract liposome and preparation method thereof | |
| CN114939072B (en) | Moisturizing and repairing freeze-dried emulsion and preparation method thereof | |
| FR2677885A1 (en) | PLANT BASED COMPOSITION, USEFUL IN COSMETOLOGY, HYGIENE OR PHARMACY AND PROCESS FOR PREPARING THE SAME. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220211 |